Congenital disorders
Tideglusib by AMO Pharma for Myotonic Dystrophy: Likelihood of Approval
Oct
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Tideglusib overview
Tideglusib (AMO-02/NP-12) is under development for the treatment of congenital and juvenile onset myotonic dystrophy and autism spectrum disorder. It is administered through the oral route. The drug candidate acts by targeting glycogen synthase kinase 3 beta and RNA ligase. The drug candidate is a disease-modifying thiazolidine derivative. The drug candidate was also under development for the treatment of Alzheimer’s disease, fragile X syndrome and progressive supranuclear palsy (PSP).
AMO Pharma overview
AMO Pharma is a biopharmaceutical company that develops novel treatments for serious and debilitating diseases. The company’s product portfolio comprises AMO-01 and AMO-02. Its AMO-01 is being developed for the treatment of autism and intellectual disabilities. It is an inhibitor of the ras-extracellular signal-regulated kinase pathway (Ras-ERK). AMO Pharma offers AMO-02 which is used for the treatment of myotonic dystrophy, CNS, neuromuscular and oncology indications among others. It is an inhibitor of glycogen synthase kinase 3 beta. The company provides target therapy areas such as central nervous system disorders, neuromuscular and Steinert’s disease. It also has operations in the US and the UK. Amo Pharma is headquartered in Leeds, England, the UK.
For a complete picture of Tideglusib’s drug-specific PTSR and LoA scores, buy the report here.
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
